Skip to content
POM-V Prescription Required Companion Animal

Eurican DAP Lyophilisate and Solvent for Suspension for Injection

Active ingredients: Canine adenovirus, Canine distemper virus, Canine parvovirus

Form

Injection

Species

Dogs

Manufacturer

Boehringer Ingelheim Animal Health UK Limited

VMD MA No.

08327/5023

What it's used for

Active immunisation of dogs to: - prevent mortality and clinical signs caused by canine distemper virus (CDV), - prevent mortality and clinical signs cause...

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Canine adenovirus + Canine d...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Eurican DAP Lyophilisate and Solvent for Suspension for Injection — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 26 Mar 2026.

Active immunisation of dogs to:
- prevent mortality and clinical signs caused by canine distemper virus (CDV),
- prevent mortality and clinical signs caused by infectious canine hepatitis virus
(CAV-1),
- reduce viral excretion during respiratory disease caused by canine adenovirus
type 2 (CAV-2),
- prevent mortality, clinical signs and viral excretion caused by canine parvovirus
(CPV)*.
Onset of immunity: 2 weeks after the second injection of the primary vaccination
course for all strains.

Revised June 2024
AN: 00737/2023 & 03367/2023Page 2 of 6
Duration of immunity: at least one year after the second injection of the primary
vaccination course and at least 2 years after the first annual booster for all strains.
Current available challenge and serological data show that protection for distemper
virus, adenovirus and parvovirus* lasts for 2 years after primary vaccination course
followed by a first annual booster. Any decision to adapt the vaccination schedule of
this veterinary medicinal product needs to be made on a case by case basis, taking
into account the vaccination history of the dog and the epidemiological context.
*Protection has been demonstrated against canine parvovirus type 2a, 2b and 2c
either by challenge (type 2b) or serology (type 2a and 2c).
Aseptically reconstitute the contents of the lyophilisate with either solvent for Eurican
DAP/DAPPi or a compatible Boehringer Ingelheim vaccine (Eurican LR, Eurican L,
Eurican Lmulti or Eurican L4) where available. Shake well before use. The entire
contents of the reconstituted vial should be administered as a single dose.
The reconstituted content shall be an opalescent yellow to orange suspension.
Inject a 1-ml dose subcutaneously according to the following schedule:
Primary vaccination:
Two injections separated by an interval of 4 weeks from 7 weeks of age.
When administered with Boehringer Ingelheim's vaccines containing rabies, the
minimum age for vaccination is 12 weeks of age.
In cases where high levels of maternally derived antibodies are suspected by the
veterinarian and the primary vaccination course was completed before 16 weeks of
age, a third injection is recommended from 16 weeks of age, at least 3 weeks after
the second injection.
Revaccination: Administer one dose 12 months after completion of the primary
vaccination course.
Dogs should be revaccinated with a single booster dose every two years after the
first annual booster

Revised June 2024
AN: 00737/2023 & 03367/2023Page 4 of 6
None.
A slight swelling (≤ 2 cm) at the injection site may commonly be observed
immediately after injection. It usually regresses within 1-6 days. This can, on some
occasions, be accompanied by slight pruritus, heat and pain at the injection site.
Transient lethargy and emesis may also be commonly observed.
Anorexia, polydipsia, hyperthermia, diarrhoea, muscle tremor, muscle weakness and
injection site cutaneous lesions may uncommonly be observed.
Hypersensitivity reactions (facial oedema, anaphylactic shock, urticaria) may rarely
occur, some of which are life-threatening. Appropriate symptomatic treatment should
promptly be provided.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Revised June 2024
AN: 00737/2023 & 03367/2023Page 3 of 6
Vaccinate healthy animals only.

Special precautions for use in animals
Apply usual aseptic procedures.
After vaccination, the live CAV-2 and CPV vaccine strains can transiently be shed
without adverse consequence for in-contact animals.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered with Eurican LR, Eurican L Eurican Lmulti or Eurican L4 vaccines (used
as solvent) where available.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day but not mixed with Rabisin vaccine.
When administered with Boehringer Ingelheim's vaccines containing rabies, the
minimum age for vaccination is 12 weeks of age.
When mixed with the Eurican LR vaccine a small and transient nodule (maximum
size 1.5 cm) at the injection site may be induced due to the presence of aluminium
hydroxide and a slight swelling (~4 cm) may occur after the injection at injection site,
regressing generally within 1-4 days.
When mixed with the Eurican L4 vaccine a swelling (less than 6 cm) may very
commonly occur at the injection site, disappearing within 8 days, anorexia may
commonly occur and vocalisation, tachycardia and tachypnoea may uncommonly be
observed. For Eurican L4, no safety data in pregnant bitches are available for the
additional inactivated strain, Leptospira Australis.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the products mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.
Lyophilisate and solvent:
Store and transport refrigerated (2 C - 8 C).
Protect from light.
Do not freeze.
Not applicable.
5. IMMUNOLOGICAL PROPERTIES
ATCvet code: QI07AD02.
Pharmacotherapeutic group: Immunologicals for Canidae, live viral vaccines for
dogs.
Vaccine against canine distemper, canine adenovirus (CAV-1 and CAV-2) and
parvovirus infections.
After administration, the vaccine induces an immune response in dogs against
distemper, adenoviroses (CAV-1 and CAV-2) and parvovirosis demonstrated by
challenge and by the presence of antibodies.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.